Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study…
<!-- Name:DistributionId Value:8827503 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Ovid Therapeutics Inc.
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with…
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people…
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapiesCollaboration with Dr.…